Ocular Therapeutix (OCUL) has shared an announcement.
Ocular Therapeutix, Inc. has appointed Pravin U. Dugel, M.D., as its new President and CEO, bringing his extensive experience in ophthalmology and biopharmaceutical leadership, following Antony C. Mattessich’s departure, which was unrelated to any company disagreements. Additionally, Nadia Waheed, M.D., is set to become the new Chief Medical Officer in May 2024, succeeding Rabia Gurses Ozden, M.D. Meanwhile, the company’s 2019 Inducement Stock Incentive Plan has been expanded to allow for more shares to be issued to incentivize key talent.
See more data about OCUL stock on TipRanks’ Stock Analysis page.
